AR129002A1 - Inhibidores de egfr - Google Patents
Inhibidores de egfrInfo
- Publication number
- AR129002A1 AR129002A1 ARP230100850A ARP230100850A AR129002A1 AR 129002 A1 AR129002 A1 AR 129002A1 AR P230100850 A ARP230100850 A AR P230100850A AR P230100850 A ARP230100850 A AR P230100850A AR 129002 A1 AR129002 A1 AR 129002A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound
- pharmaceutical composition
- egfr inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263327631P | 2022-04-05 | 2022-04-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR129002A1 true AR129002A1 (es) | 2024-07-03 |
Family
ID=86286433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230100850A AR129002A1 (es) | 2022-04-05 | 2023-04-05 | Inhibidores de egfr |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20250236608A1 (enExample) |
| EP (1) | EP4504719A1 (enExample) |
| JP (1) | JP2025512957A (enExample) |
| KR (1) | KR20250012554A (enExample) |
| CN (1) | CN119325471A (enExample) |
| AR (1) | AR129002A1 (enExample) |
| AU (1) | AU2023250382A1 (enExample) |
| CA (1) | CA3247645A1 (enExample) |
| IL (1) | IL315980A (enExample) |
| MX (1) | MX2024012267A (enExample) |
| PY (1) | PY2325218A (enExample) |
| TW (1) | TW202404590A (enExample) |
| UY (1) | UY40220A (enExample) |
| WO (1) | WO2023196283A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025080786A1 (en) * | 2023-10-11 | 2025-04-17 | Blueprint Medicines Corporation | Salt and solid forms of an egfr inhibitor |
| WO2025080784A1 (en) * | 2023-10-11 | 2025-04-17 | Blueprint Medicines Corporation | Egfr inhibitors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012066122A1 (en) * | 2010-11-18 | 2012-05-24 | Syngenta Participations Ag | 2 - (pyridin- 2 -yl) -quinazoline derivatives and their use as microbicides |
| CN110498804A (zh) * | 2018-05-18 | 2019-11-26 | 山东轩竹医药科技有限公司 | 喹唑啉衍生物类酪氨酸激酶抑制剂的新用途 |
| TW202012391A (zh) * | 2018-07-04 | 2020-04-01 | 日商第一三共股份有限公司 | 二芳基醚型喹唑啉衍生物 |
| JP7752617B2 (ja) | 2019-12-23 | 2025-10-10 | ブループリント メディシンズ コーポレイション | Ｅｇｆｒの変異型の阻害剤 |
-
2023
- 2023-03-31 TW TW112112529A patent/TW202404590A/zh unknown
- 2023-04-04 WO PCT/US2023/017384 patent/WO2023196283A1/en not_active Ceased
- 2023-04-04 EP EP23721090.1A patent/EP4504719A1/en active Pending
- 2023-04-04 KR KR1020247036844A patent/KR20250012554A/ko active Pending
- 2023-04-04 JP JP2024559157A patent/JP2025512957A/ja active Pending
- 2023-04-04 CA CA3247645A patent/CA3247645A1/en active Pending
- 2023-04-04 PY PY202302325218A patent/PY2325218A/es unknown
- 2023-04-04 IL IL315980A patent/IL315980A/en unknown
- 2023-04-04 US US18/853,933 patent/US20250236608A1/en active Pending
- 2023-04-04 CN CN202380044824.6A patent/CN119325471A/zh active Pending
- 2023-04-04 AU AU2023250382A patent/AU2023250382A1/en active Pending
- 2023-04-05 AR ARP230100850A patent/AR129002A1/es unknown
- 2023-04-10 UY UY0001040220A patent/UY40220A/es unknown
-
2024
- 2024-10-03 MX MX2024012267A patent/MX2024012267A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN119325471A (zh) | 2025-01-17 |
| KR20250012554A (ko) | 2025-01-24 |
| IL315980A (en) | 2024-11-01 |
| US20250236608A1 (en) | 2025-07-24 |
| AU2023250382A1 (en) | 2024-11-14 |
| WO2023196283A1 (en) | 2023-10-12 |
| MX2024012267A (es) | 2024-11-08 |
| JP2025512957A (ja) | 2025-04-22 |
| CA3247645A1 (en) | 2023-10-12 |
| TW202404590A (zh) | 2024-02-01 |
| PY2325218A (es) | 2023-10-17 |
| EP4504719A1 (en) | 2025-02-12 |
| UY40220A (es) | 2023-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR126251A1 (es) | Inhibidores de cdk2 | |
| CO2026005655A2 (es) | Inhibidor de pan-kras y uso del mismo en medicinas | |
| MX2022013974A (es) | Inhibidor de sos1 que contiene fosforo. | |
| FI4175951T3 (fi) | Hpk1-estäjiä ja niiden käyttötapoja | |
| CL2021003202A1 (es) | Compuestos de pirrolidina | |
| AR127645A1 (es) | Inhibidores de molécula pequeña de proteasa 1 específica de ubiquitina (usp1) y usos de los mismos | |
| PH12023550160A1 (en) | Combinations for the Treatment of Cancer | |
| AR128717A1 (es) | Formas sólidas, sales y procesos de preparación de un inhibidor de cdk2 | |
| CL2025000970A1 (es) | Compuesto inhibidor de parg | |
| CL2023003758A1 (es) | Pirimidinil-pirazoles sustituidos como inhibidores de cdk2 | |
| DOP2024000146A (es) | Inhibidores de parp7 | |
| PE20221768A1 (es) | Inhibidores de egfr | |
| MX2023004998A (es) | Metodo para tratar canceres con derivados de quinazolina sustituida con alquino. | |
| AR127247A1 (es) | Inhibidores de cdk2 de ciclopentilpirazol | |
| CL2023000857A1 (es) | Inhibidores line-1 para tratar la enfermedad | |
| CO2025004701A2 (es) | Métodos de tratamiento del cáncer usando derivados de isoquinolina o 6-aza-quinolina | |
| CL2025000672A1 (es) | Compuestos derivados de aminopirimidina, inhibidores de cdk2; composición farmacéutica; uso para tratar cáncer. | |
| AR128257A1 (es) | Compuestos y composiciones para tratar afecciones relacionadas con la actividad de sting | |
| AR127496A1 (es) | Compuestos de cd73 | |
| CO2025015732A2 (es) | Inhibidores de cdk2 | |
| AR126196A1 (es) | Proceso para preparar inhibidores de egfr | |
| MX2024012267A (es) | Inhibidores de egfr | |
| CO2025016753A2 (es) | Inhibidores de gsk3α y métodos de uso de estos | |
| WO2024151638A3 (en) | Compounds for fgfrs inhibitors | |
| ECSP078015A (es) | 4-anilino-3-quinolinocarbonitrilos para el tratamiento de cáncer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |